Vista Pharmaceuticals Ltd
Incorporated in 1992, Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulations
- Market Cap ₹ 52.7 Cr.
- Current Price ₹ 13.6
- High / Low ₹ 19.7 / 7.95
- Stock P/E
- Book Value ₹ 9.94
- Dividend Yield 0.00 %
- ROCE -10.3 %
- ROE -17.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Promoter holding has increased by 7.63% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -49.0% over past five years.
- Promoter holding is low: 35.4%
- Company has a low return on equity of -8.70% over last 3 years.
- Company has high debtors of 4,106 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.62 | 7.47 | 8.30 | 13.75 | 15.38 | 24.18 | 28.92 | 31.07 | 22.76 | 1.27 | 0.39 | 1.00 | 8.15 | |
4.52 | 6.65 | 7.08 | 11.05 | 12.78 | 21.12 | 23.59 | 29.84 | 27.56 | 3.00 | 1.66 | 5.32 | 15.58 | |
Operating Profit | -0.90 | 0.82 | 1.22 | 2.70 | 2.60 | 3.06 | 5.33 | 1.23 | -4.80 | -1.73 | -1.27 | -4.32 | -7.43 |
OPM % | -24.86% | 10.98% | 14.70% | 19.64% | 16.91% | 12.66% | 18.43% | 3.96% | -21.09% | -136.22% | -325.64% | -432.00% | -91.17% |
0.01 | 0.01 | 0.03 | 0.01 | 0.02 | 0.06 | 0.40 | 2.95 | 3.75 | 0.20 | 0.17 | 0.40 | 0.63 | |
Interest | 0.01 | 0.01 | 0.00 | 0.41 | 0.77 | 0.88 | 1.57 | 1.67 | 1.54 | 1.55 | 0.90 | 1.34 | 1.27 |
Depreciation | 0.64 | 0.64 | 0.77 | 1.05 | 1.02 | 1.02 | 1.34 | 1.36 | 1.35 | 0.73 | 0.62 | 0.62 | 0.69 |
Profit before tax | -1.54 | 0.18 | 0.48 | 1.25 | 0.83 | 1.22 | 2.82 | 1.15 | -3.94 | -3.81 | -2.62 | -5.88 | -8.76 |
Tax % | -7.79% | 50.00% | 2.08% | -8.80% | 8.43% | -1.64% | 22.70% | 18.26% | 6.60% | 47.24% | 66.03% | 3.57% | |
-1.66 | 0.08 | 0.47 | 1.36 | 0.77 | 1.25 | 2.19 | 0.94 | -3.68 | -2.01 | -0.89 | -5.66 | -8.31 | |
EPS in Rs | -0.22 | 0.01 | 0.06 | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -2.22 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -18% |
5 Years: | -49% |
3 Years: | -65% |
TTM: | 156% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -23% |
TTM: | -2697% |
Stock Price CAGR | |
---|---|
10 Years: | 29% |
5 Years: | -6% |
3 Years: | -2% |
1 Year: | 40% |
Return on Equity | |
---|---|
10 Years: | -2% |
5 Years: | -7% |
3 Years: | -9% |
Last Year: | -17% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15.00 | 15.00 | 15.00 | 5.00 | 5.00 | 5.31 | 5.83 | 6.07 | 6.07 | 7.36 | 7.36 | 7.51 | 8.84 |
Reserves | -6.45 | -6.37 | -5.91 | 5.44 | 6.21 | 11.29 | 26.03 | 29.73 | 23.57 | 25.49 | 28.09 | 23.04 | 29.74 |
0.00 | 0.00 | 0.00 | 4.04 | 7.88 | 11.33 | 11.06 | 11.17 | 15.47 | 10.71 | 12.55 | 9.96 | 9.26 | |
6.19 | 5.82 | 4.97 | 8.30 | 7.29 | 13.69 | 10.08 | 5.79 | 6.01 | 9.05 | 7.59 | 15.52 | 8.43 | |
Total Liabilities | 14.74 | 14.45 | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 56.27 |
12.96 | 12.45 | 11.69 | 10.73 | 9.96 | 13.46 | 17.67 | 20.52 | 20.66 | 19.93 | 19.33 | 19.74 | 19.60 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 7.11 | 8.54 | 8.78 | 9.08 | 9.08 | 9.33 | 9.64 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 |
1.78 | 2.00 | 2.37 | 12.05 | 16.42 | 26.17 | 28.20 | 23.67 | 21.66 | 23.56 | 27.15 | 26.94 | 27.01 | |
Total Assets | 14.74 | 14.45 | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 56.27 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.26 | 0.21 | -0.09 | -3.53 | -2.50 | 2.57 | -4.58 | 3.30 | 0.80 | -6.75 | -0.99 | -1.71 | |
-0.12 | -0.11 | 0.01 | -0.09 | -0.24 | -3.61 | -10.61 | -5.65 | -1.73 | -0.30 | -0.01 | -1.27 | |
-0.01 | -0.10 | 0.00 | 3.63 | 3.07 | 6.36 | 11.22 | 1.43 | 0.28 | 6.96 | 0.94 | 3.11 | |
Net Cash Flow | 0.13 | 0.00 | -0.08 | 0.00 | 0.34 | 5.32 | -3.98 | -0.92 | -0.64 | -0.09 | -0.07 | 0.13 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 0.00 | 0.00 | 45.30 | 299.70 | 231.15 | 136.01 | 137.06 | 98.09 | 164.86 | 623.66 | 9,789.49 | 4,106.25 |
Inventory Days | 176.37 | 106.33 | 51.61 | 10.20 | 96.66 | 184.54 | 249.51 | 161.60 | 147.59 | 4,840.00 | 9,203.92 | 990.53 |
Days Payable | 323.59 | 263.43 | 323.11 | 359.43 | 236.24 | 293.13 | 208.80 | 75.56 | 78.67 | 2,555.00 | 5,297.43 | 1,007.30 |
Cash Conversion Cycle | -147.23 | -157.11 | -226.21 | -49.53 | 91.57 | 27.41 | 177.77 | 184.14 | 233.77 | 2,908.66 | 13,695.97 | 4,089.48 |
Working Capital Days | -448.69 | -186.16 | -110.38 | 98.75 | 205.76 | 92.23 | 202.32 | 197.71 | 240.55 | 2,261.85 | 14,955.64 | 5,201.25 |
ROCE % | -16.31% | 2.21% | 5.42% | 14.09% | 9.53% | 8.93% | 12.39% | 6.27% | -5.21% | -5.10% | -3.76% | -10.26% |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 21 Apr
- Closure of Trading Window 29 Mar
- Outcome Of Circular Resolutions Passed By Board Of The Company By Circulation On 13.02.2024 Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 13 Feb
- Intimation Of Appointment Of Company Secretary & Compliance Officer; 10 Feb
- Outcome Of Board Meeting Under Regulation 30 Read With 33 (3) (C) Of SEBI (LODR) Regulations, 2015 10 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers, produce markets, and distributes pharmaceutical products. The company has its USFDA Approved Manufacturing Facility in India and its Marketing and Distribution Center in the USA.